CV Sciences, Inc. (CVSI) Fair Value 2026

CVSI · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (44/100)

Quick Summary — As of 2026-10-07, CV Sciences, Inc. (CVSI) trades at $0.01. QOC: 5.4/10. Value Trap Risk: 44/100 (WARN). 1/13 models active.

Key Facts

Ticker
CVSI
Price
$0.01
Quality Score
5.4/10
Value Trap Risk
44/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +120.8% upside with 35% confidence
Risk: Value Trap score of 44 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CVSI?

1 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.03 +120.8%

All Models Active

All 1 models are displayed above.

What Is CV Sciences, Inc. (CVSI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for CV Sciences, Inc.. Trading at $0.01 against an estimated intrinsic value of $0.03, 1 of 1 active models flag meaningful upside of +120.8% at the median.

What Do the Models Say About CVSI?

1 of 13 models are currently active for CVSI. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CVSI Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, CVSI ranks #69 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, CV Sciences, Inc. competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CVSI a Value Trap?

CirclFi's Value Trap algorithm assigns CVSI a score of 44/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for CV Sciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, CV Sciences, Inc. is rated at 5.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CVSI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CVSI's 1 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CV Sciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

TLPHTalphera, Inc.QOC 5.7BFRIBiofrontera Inc.QOC 5.4VRNOVerano Holdings Corp.QOC 5.7YCBDcbdMD, Inc.QOC 5.3BIOABioAge Labs, Inc.QOC 5.8CGCCanopy Growth CorporationQOC 5.3BUDZWEED, Inc.QOC 4.2BCRXBioCryst Pharmaceuticals, Inc.QOC 8.4AYTUAytu BioPharma, Inc.QOC 6.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: TLPH · BFRI · VRNO · YCBD · BIOA · CGC · BUDZ · BCRX · AYTU · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CVSI?

6 companies across all industries closest to CVSI’s Quality of Company score of 5.4/10.

ADNHAdvent Technologies Holdings, Inc.QOC 5.4ANEBAnebulo Pharmaceuticals, Inc.QOC 5.4RTONRight On Brands, Inc.QOC 5.4LESLLeslie's, Inc.QOC 5.4CDLXCardlytics, Inc.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ADNH · ANEB · RTON · LESL · CDLX · NVDA

Where Does CVSI Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CVSI is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About CV Sciences, Inc.’s Valuation?

What is CV Sciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for CV Sciences, Inc. (CVSI). The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CVSI overvalued or undervalued right now?

At $0.01, 1 of 1 active models suggest CVSI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits CV Sciences, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.4 mean for CVSI?

CV Sciences, Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CVSI?

CirclFi analyzes CVSI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CVSI a value trap in 2026?

CV Sciences, Inc.'s Value Trap score is 44/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns CV Sciences, Inc. (CVSI) a Quality of Company score of 5.4/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/CVSI/ · Methodology
Primary sources for this CVSI valuation
  • Financial statements: CV Sciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001510964) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CVSI as of ; valuations recomputed .